CDNA vs SYK
CareDx, Inc vs Stryker Corporation — AI-powered side-by-side comparison
VS
SYK
Stryker Corporation
59
Buy
| Metric | CDNA | SYK |
|---|
| AI Score |
69
|
59
|
| Price |
$50.02
|
$330.05
|
| P/E Ratio |
23.61×
|
33.98×
|
| ROE |
-7.0%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.6%
|
65.2%
|
| Debt / Equity |
0.05×
|
0.62×
|
| Dividend Yield |
0.0%
|
1.1%
|
| RSI (14) |
75.0
|
44.6
|
| Beta |
2.419
|
0.771
|
| Expected Upside |
—
|
+13.1%
|
AI Committee View
Current Innellis committee reasoning for CDNA versus SYK.
CDNA leads by 10 points.
CDNA scores 69/100 (Buy) versus SYK at 59/100 (Buy).
CDNA Committee View
100% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 32.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 227.0% YoY — Growth
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
SYK Committee View
60% agreement
5 analysts
Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 27.7% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 35.2 is moderate-to-rich — Value
- Price-to-book of 6.0x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical